RxDoctor Payments Data

Philip Lesueur, MD

Internal Medicine · Sierra Vista, AZNPI 1194161505

Payments from drug & device makers

$874in general payments, 2019–2025

Across 48 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96
  • GSK$79
  • Bayer$75
  • Abbott$68
  • Amgen$67
  • Sanofi Pasteur Inc.$56
  • plus $433 from 14 others

What the payments were for

  • Food & beverage$874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$874 in reported general payments places this provider in the 70th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$253,001
Medicare patients
661
Services billed
3,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZemairaAlpha-1-Proteinase Inhibitor11$97,588
EliquisApixaban93$94,202
OzempicSemaglutide51$63,201
JardianceEmpagliflozin41$50,633
Repatha SureclickEvolocumab28$34,126
XareltoRivaroxaban21$30,200
JanuviaSitagliptin Phosphate23$29,682
TrulicityDulaglutide17$28,850
ProliaDenosumab16$27,781
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$23,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$19,521
Advair HfaFluticasone Propion/Salmeterol28$16,809
MounjaroTirzepatide12$14,319
MyrbetriqMirabegron13$13,745
Bydureon BciseExenatide Microspheres12$10,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$94,20293 claims
Novo NordiskOzempic, Novolog$35$67,47264 claims
Lilly USA, LLCTrulicity, Mounjaro$14$43,16929 claims
GSKTrelegy Ellipta, Incruse Ellipta$79$28,45139 claims
AmgenProlia$67$27,78116 claims
Astellas Pharma US IncMyrbetriq$43$13,74513 claims
AstraZenecaSymbicort$46$5,88117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Sierra Vista

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →